#London #United Kingdom #BioTech Innovations #CAR therapy #CREATE Medicines

CREATE Medicines Takes the Stage at the 2026 Jefferies Global Healthcare Conference

CREATE Medicines, Inc., a cutting-edge player in the biotechnology sector, is gearing up for an exciting presentation at the upcoming 2026 Jefferies Global Healthcare Conference. This high-profile event is scheduled to take place from November 16 to 19, 2026, at the renowned Waldorf Hilton and ME London. Attendees can look forward to insightful one-on-one meetings with members of CREATE's senior management team, positioned to engage with investors and prospective partners regarding their revolutionary research.

The discussions will primarily focus on CREATE's advancements in in vivo multi-immune programming, particularly highlighting their four clinical-stage CAR (Chimeric Antigen Receptor) programs that target both oncology and autoimmune diseases. The biotechnology firm has earned recognition as a frontrunner in in vivo CAR therapy, having successfully treated over 80 patients, making their clinical dataset the largest in this field.

CREATE's proprietary technology employs a unique mRNA-Lipid Nanoparticle (mRNA-LNP) platform that can program immune cells within the patient's body. This innovative approach enables both temporary and stable CAR expression through direct in vivo applications utilizing RNA. Among their clinical-stage products are CRT-402, an in vivo CAR targeting CD19; MT-303, a GPC3-targeted in vivo CAR; MT-302, a TROP2-targeted in vivo CAR; and MT-304, focused on HER2.

The two key figures representing CREATE at this conference will be Daniel Getts, PhD, the CEO and Co-Founder, alongside Matthew Maurer, MD, the Chief Medical Officer. Their presence underscores the importance of collaboration and exchange within the biopharmaceutical industry, especially as clinical trials progress and new partnerships emerge.

For investors eager to secure meetings with CREATE at the conference, contact through Jefferies representatives is recommended to ensure personalized discussions. Interested parties looking into partnership opportunities can reach out via email to [email protected].

About CREATE Medicines

CREATE Medicines is leading the charge in developing CAR therapies, aiming to transform treatment options for cancer and autoimmune diseases. Their mRNA-LNP platform facilitates the programming of immune cells within the body, providing scalable and accessible immunotherapy solutions. With proven validation in human subjects, CREATE is at the forefront of significant breakthroughs that promise enhanced therapeutic outcomes.

For further details, visit create medicines.com and follow them on LinkedIn, X (formerly Twitter), and Bluesky for updates on their progress and initiatives.

Conclusion

As CREATE Medicines prepares for their participation at the Jefferies Global Healthcare Conference, they not only highlight their clinical achievements but also invite potential collaborations that can steer future innovations in healthcare. Their commitment to pioneering CAR therapy makes this a highly anticipated event for stakeholders in the life sciences sector.